A Pancreatic Cancer Screening Study for High Risk Individuals
https://www.facingourrisk.org/research-clinical-trials/study/95/pancreatic-cancer-screening-study-for-high-risk-people
Clinicaltrials.gov identifier:
NCT03250078 (https://clinicaltrials.gov/show/NCT03250078)
Prevention
Screening study to detect pancreatic cancer and precancer
Study Contact Information:
Contact: Tammy Lo, APRN by phone: 203-855-3551 or by email
Contact: Pramila Krumholtz, RN by phone: 203-739-7997 by email
Principal Investigator: Richard Frank, MD
About the Study
The purpose of this study is to screen and detect pancreatic cancer and precancer in people with a strong family history of pancreatic cancer, or people with an inherited mutation and at least one first- or second-degree relative with pancreatic cancer. This includes people with Lynch syndrome (a mutation in EPCAM, MLH1, MSH2, MSH6, or PMS2) or an inherited mutation in BRCA1, BRCA2, CDKN2A, ATM or PALB2.
Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer.
What the Study Involves
- Participants will undergo a five-minute psychological survey and donation of a blood sample every 6 months for 3 years.
- MRI will be performed annually for 3 years (4 in total). Cost of MRI will be covered by the study.
- Any abnormalities on the MRI will be reviewed by a multi-disciplinary tumor board and discussed with the study participant.
This Study is Open To:
Men and women 50-80 years of age can participate if:
- They have a strong family history of pancreatic cancer and
- at least two first-degree relatives with pancreatic cancer
- at least three first-, second-, or third-degree relatives with pancreatic cancer with at least one pancreatic cancer in a first degree relative
- They have Lynch syndrome (a mutation in EPCAM, MLH1, MSH2, MSH6, or PMS2) or an inherited mutation in BRCA1, BRCA2, CDKN2A, ATM or PALB2 and have at least one first- or second-degree relative with pancreatic cancer.
This Study is Not Open To:
People are excluded if they:
- Have a prior history of pancreatic cancer or have metastatic cancer
- Have a cancer that required post-treatment chemotherapy within the past 5 years
- Received chemotherapy within the past 6 months
- Have hereditary pancreatitis
- Are known to have a severe reaction to a gadolinium contrast or an MRI exam
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.